Approval of first US cancer gene therapy ‘a significant milestone … – Kankakee Daily Journal
|
Approval of first US cancer gene therapy ‘a significant milestone …
Kankakee Daily Journal In an interview with The Washington Post on Monday, U.S. Food and Drug Administration Commissioner Scott Gottlieb said the medical and scientific community … |
Neurology Advisor |
Risk of Stroke, Mortality Reduced With High Stem Cell Factor
Neurology Advisor HealthDay News — High levels of stem cell factor (SCF) are associated with reduced risk of mortality and cardiovascular events, according to a study published in the Journal of Internal Medicine. Harry Björkbacka, PhD, from Lund University in Sweden … |
|
New Project Will Explore Gene Therapies in Hemophilia Treatments
AJMC.com Managed Markets Network The CoreHEM strives to develop a “core set” of outcomes to calculate gene therapy effectiveness by combing ideas form clinicians, researchers, patients, product manufacturers, public and private payers, and international government agencies. |
CNA Finance |
ITUS Provides Update on Cancer Detection Technology and New CAR–T Initiative for Ovarian Cancer
Markets Insider The Wistar Institute’s CAR-T technology focuses initially on Ovarian Cancer with potential future applications in Prostate, Pancreatic and other cancers as well. The engineered T–cells will use the Follicle Stimulating Hormone (FSH) to target ovarian … ITUS Corp. (ITUS) Stock: Gaining Big On Clinical UpdateCNA Finance (press release) |
Cancer Research UK |
Promising immunotherapy drug now available for some lung cancer patients in England
Cancer Research UK Rose Gray, Cancer Research UK’s senior policy adviser, welcomed the decision to provide the promising drug, which is a kind of immunotherapy. “Immunotherapies such as Nivolumab are showing great promise for cancer patients, so it’s fantastic that this … Life-extending lung cancer drug will be made available on the NHSCambridge News Nivolumab to be made available to lung cancer patients in England and Wales, says NICEThe Pharmaceutical Journal |